source
- Vir Biotechnology appoints David Liu as chief medical officer to steer hepatitis D phase 3 and cancer programsVir Biotechnology announced the appointment of David Liu, M.D., Ph.D., as its new chief medical officer. Liu comes from a recent stint as CMO at Nuvation Bio and has held senior roles at AstraZene…
- Eli Lilly’s trillion-dollar market cap mirrors Dodgers’ big-spending dominanceThe piece draws a parallel between Eli Lilly and the Los Angeles Dodgers, noting that both organizations dominate their fields by spending heavily. Lilly recently became the first pharmaceutical co…